Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

Doing Business with BARDA

2019 Novel Coronavirus Medical Countermeasure Partnership Opportunities

BARDA is continuing to work with its partners to identify promising medical countermeasures and technologies to combat the 2019 novel coronavirus. Now, there are three ways your company or organization can partner with BARDA to fight the ongoing novel coronavirus outbreak.

Coronavirus
Test tubes
handshake
BARDA BAA Areas of Interest for Coronavirus Medical Countermeasures
EZ-BAA for Molecular Diagnostics and Nonclinical Assays Request a
USG CoronaWatch Meeting



BARDA BAA: COVID-19 Areas of Interest

BARDA is investing in an array of medical countermeasures to diagnose, treat, or protect against the 2019 novel coronavirus under the BARDA Broad Agency Announcement (BAA-18-100-SOL-00003). Specifically, BARDA is pursuing the following products or technologies:

  • Diagnostic assays for human pan-coronaviruses
  • Point-of-Care diagnostic assays for SARS-CoV-2 virus
  • Diagnostic assay to detect COVID-19 disease
  • Nonclinical model
  • Vaccines for novel coronavirus
  • Therapeutics for novel coronavirus
  • Ventilators
  • Immunomodulators or therapeutics targeting lung repair
  • Pre-exposure and post-exposure prophylaxis for novel coronavirus exposure
  • Respiratory protective devices
  • Advanced Manufacturing Technologies

To learn more, including targets for product maturity under this announcement, see the newly revised BARDA Broad Agency Announcement.

Novel Coronavirus EZ-BAA

To spur innovation, BARDA has issued its business-friendly, streamlined Easy Broad Agency Announcement (EZ-BAA) to support a number of new medical countermeasures to fight the COVID-19 outbreak.  Under the EZ-BAA, BARDA is looking for:

  • Molecular diagnostic assay for SARS-CoV-2 virus on existing FDA-cleared platform
  • Point-of-care diagnostic assay for detection of SARS-CoV-2 virus
  • Diagnostic assay for detection of COVID-19 disease
  • Nonclinical model development and screening for SARS-CoV-2 virus
  • Alternate vaccine delivery/administration and adjuvants
  • Advanced manufacturing technologies

To learn more, see the Novel Coronavirus EZ-BAA.

Request a USG CoronaWatch Meeting

If you are interested in partnering with the federal government on a COVID-19 medical countermeasure, submit your ideas to a platform that reaches a host of potential federal partners!  The federal government established a single point of entry for product developers to submit their research on 2019 novel coronavirus medical countermeasures. Submit a brief description and supporting materials through our CoronaWatch Portal.


  • This page last reviewed: March 24, 2020